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Abstract
Glycodelin is the major progesterone-
regulated lipocalin protein of the repro-
ductive axis. It has contraceptive and immu-
nomodulatory functions, and it may play
an important role in differentiation and
glandular morphogenesis. The aim of this
study was to investigate the expression of
glycodelin in three clinical settings: in the
fertile window, in the window of implanta-
tion, and in ovarian serous carcinoma, with
special attention to changes in tissue
differentiation.
Glycodelin is a uterine secretory glyco-
protein that inhibits sperm-egg binding,
and is not normally secreted during the
fertile window at midcyle. This phase of the
menstrual cycle was specifically addressed
in respect to induced secretion of contra-
ceptive glycodelin. Evidence showed that a
levonorgestrel-releasing IUD is accom-
panied by inappropriate expression of
glycodelin in endometrium between days
7 and 16 of the menstrual cycle (6 of 6 cases).
The same was also found in copper-IUD-
wearing women, but less frequently (4 of
11 cases, P < 0.0345). Experiments
employing in situ hybridization localized
glycodelin mRNA into endometrial glands
in the midcycle endometrium, confirming
the cellular site of synthesis.
Another group of contraceptive users, in
whom uterine glycodelin secretion was
studied during the fertile window, were
levonorgestrel subdermal implant-wearing
women. Of the endometrial specimens from
these women, 80% stained positive for
glycodelin. The endometrial morphology of
these women showed proliferative (71%),
inactive/weakly proliferative (19%),
menstrual or regenerating (6.5%), and other
patterns  (2.8%). Of these, 79%, 71%,
100%, and 100% were glycodelin-positive.
During the midcycle, when glycodelin is
not normally expressed, of 19 cases 89%
showed glycodelin expression.
Another point of interest is the window
of implantation that in a normal menstrual
cycle spans from LH+4/5 to LH+10. Factors
affecting glycodelin expression during the
phase of uterine receptivity were chosen in
view of the immunosuppressive properties
of glycodelin and its putative role in feto-
maternal defense mechanisms. In women
with COH (controlled ovarian hypersti-
mulation), endometrium is exposed to high
concentrations of ovarian steroids and other
substances. In such women, the proportion
of glycodelin-positive endometrial cells was
elevated above values in normal controls.
This was evident throughout the window
of implantation. Glycodelin was present in
the endometrial glands, but not in the
stroma or surface epithelium. A positive
correlation appeared between glycodelin
expression and serum estradiol levels (r =
0.5, P < 0.001) in normal menstrual cycles,
and glycodelin and advanced histology in
COH cycles (r = 0.63, P = 0.01). Neither
LH nor progesterone serum levels were
correlated with endometrial glycodelin
expression.
Because ethical constraints limit studies
on endometrium during the peri-
implantation phase of a fertile cycle, the
donor oocyte model was chosen for
investigation of candidate endometrial
markers in respect to uterine receptivity.
Endometrial biopsies from cycle days 21 to
23 of oocyte recipients undergoing mock
hormonal treatment cycles were evaluated by
Erik Mandelin
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standard histological criteria and by
immunohistochemical staining for
glycodelin and αvβ3 integrin. Oocyte
recipients underwent identical hormonal
replacement protocols for both the mock
treatment cycle and the actual oocyte
donation cycle. Endometrial histology of
these women showed 62 (61.3%) in-phase,
34 (33.7%) dyssynchronous, 2 (2.0%)
immature, and 3 (3.0%) advanced
maturation. The clinical outcomes of patients
with either in-phase or dyssynchronous
endometria were similar. Strong correlations
existed between endometrial glandular
dating and either glycodelin- or αvβ3
integrin-immunostaining intensity (P <
0.001 for both). Glycodelin and αvβ3
integrin-immunostaining intensities were
also highly correlated with each other (P <
0.001).
In ovarian serous carcinomas from 460
patients, we determined glycodelin
expression by immunohistochemistry of
tissue microarrays, and analyzed the results
in relation to the progesterone receptors PRA
(progesterone receptor subtype A) and PRB
(progesterone receptor subtype B), to clinical
parameters, and to survival. Glycodelin was
localized in the cytoplasm of tumor cells,
whereas vascular endothelium in tumor tissue
was glycodelin-negative. Glycodelin
expression was more frequent in well-
differentiated (grade I, 79%) than in poorly
differentiated carcinomas (grade III, 51%, P
< 0.0001), and also more frequent in early
than in advanced stage carcinomas (P =
0.002). Cytoplasmic glycodelin was often co-
expressed with nuclear PRA and PRB.
Whereas this was not consistent in all
tumors, a positive correlation existed in the
tumor between the presence of glycodelin
and progesterone receptors (P < 0.02), but
not between the presence or absence of
glycodelin in the tumor and the CA-125
serum concentration. Although in
multivariate analysis glycodelin was not an
independent variable, those patients with
glycodelin-expressing tumors showed a
higher 5-year overall survival than did those
whose tumors were glycodelin-negative
(55% vs. 39%, P < 0.0001, hazard ratio in
univariate analysis 0.57, CI 0.44-0.74). In
the patients with grade I tumors or stage
III disease, this difference was pronounced.
In the latter group, the 10-year survival
probability of those with glycodelin-
positive tumors was more than twice as high
as that of  those with glycodelin-negative
tumors. This also occurred within well-
defined clinical categories, e.g., in stage III/
grade II and stage III/grade III carcinomas,
in which patients with glycodelin-positive
tumors exhibited a significantly better 10-
year overall survival than did those with
glycodelin-negative tumors.
Based on the potent inhibitory activity of
glycodelin on sperm-egg binding and
secretion into uterine fluid, in IUD and
subdermal-implant-wearing women,
glycodelin secretion during the otherwise
fertile window may thus lead, before
fertilization, to exposure of sperm to
contraceptive glycodelin. This may
contribute to the effectiveness of such
contraceptive devices. Studies of the window
of implantation showed oocyte donors
undergoing COH treatment to have
significantly higher endometrial glycodelin
expression throughout the implantation
window than did women with natural cycles.
Endometrial glycodelin expression
frequently occurred in progesterone/
estrogen- stimulated mock cycles. In ovarian
serous carcinoma, glycodelin expression is
related to differentiation and offers a better
prognosis.
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1. Introduction
In the 1970s and 1980s, several researchers
were involved in the identification and
isolation of a protein in the amniotic fluid,
human placenta, pregnancy decidua and
seminal plasma, and gave it various names,
independently of each other, according to the
source or physicochemical characteristics.
Names suggested included α-uterine protein
(Horne et al., 1982), placental α2-globulin
(Petrunin et al., 1976), chorionic α2-
microglobulin (Petrunin et al., 1980),
placental protein 14 (Bohn et al., 1982),
progesterone-associated endometrial protein
(Kämäräinen et al., 1991), progestagen-
dependent endometrial protein (PEP) (Joshi
et al., 1980b), pregnancy-associated endo-
metrial α2-globulin (α2-PEG) (Bell et al.,
1985; Bell, 1986), and human β-lacto-
globulin homolog (Bell et al., 1987; Huhtala
et al., 1987; Seppälä et al., 1987a).
Subsequent studies revealed that all these
proteins were identical in respect to their
immunological properties or primary
structure or both (Sutcliffe et al., 1982; Bell
and Bohn, 1986; Julkunen et al., 1986c; Bell
et al., 1987; Huhtala et al., 1987; Julkunen
et al., 1988; Garde et al., 1991; Seppälä et
al., 1998a). The name glycodelin was
introduced for all these proteins because no
previous names accurately reflected all the
sites of glycodelin synthesis. The name
glycodelin also emphasizes the importance
of glycosylation for the biological activity
of the protein (Seppälä et al., 2002).
2. Glycodelin
2.1. Protein
Glycodelin is a glycoprotein that belongs to
the lipocalin superfamily (Huhtala et al.,
1987; Julkunen et al., 1988). Lipocalins are
small, mostly extracellular proteins found in
vertebrates and invertebrate animals, plants,
and bacteria. They perform transport
functions and bind hydrophobic ligands such
as retinoids, steroids, and lipids. Lipocalins
also have other functions including
modulation of cell growth and metabolism,
regulation of immune response, odor
reception, tissue development, and animal
behavior (Åkerström et al., 2000).
Glycodelin consists of 180 amino acids,
18 of which correspond to a signal peptide
(Julkunen et al., 1988). Amniotic fluid
glycodelin has a molecular mass of 28kDa
by SDS-PAGE, and in gel filtration,
glycodelin behaves as a homodimeric
complex with a molecular mass of 50 to 60
kDa (Joshi et al., 1980a; Bohn et al., 1982;
Joshi, 1983; Bell, 1986). The predicted
molecular mass for the mature polypeptide
is 18 787 kDa (Julkunen et al., 1988).
Several differentially glycosylated gly-
codelin isoforms are known. Amniotic fluid
glycodelin-A and seminal fluid glycodelin-
S, sharing the same protein core, are in-
distinguishable from each other after
deglycosylation and desialylation in both
SDS-PAGE and isoelectric focusing
(Koistinen et al., 1996). Glycodelin-A and
Erik Mandelin
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glycodelin-S contain 17.5% carbohydrates
(Bohn et al., 1982), linked to two of the three
potential N-glycosylation sites at
Asparagine-28 and Asparagine-63, whereas
Asparagine-85 is not glycosylated (Julkunen
et al., 1988; Dell et al., 1995; Morris et al.,
1996).
Yao and coworkers recently (1998)
characterized a factor in human follicular
fluid which potently inhibited the binding
of spermatozoa to the zona pellucida.
Comparative studies with glycodelin revealed
that this factor, zona binding inhibitory
factor-1 (ZIF-1), is a glycodelin isoform (Chiu
et al., 2003b). Glycodelin-A and ZIF-1 have
the same molecular mass in SDS-PAGE both
before and after deglycosylation, and the first
25 N-terminal aminoacids of ZIF-1 are
identical to those of glycodelin-A. Proteolytic
digestion with trypsin and pepsin of
deglycosylated ZIF-1 and glycodelin-A
results in identical peptide patterns. The
isoelectric point of ZIF-1 is 4.2 to 4.8, i.e.,
it is more acidic than glycodelin-A (pI = 4.5
to 5.2) and glycodelin-S (pI = 4.9 to 5.6).
Based on its follicular fluid origin, ZIF-1 has
been renamed glycodelin-F (Chiu et al.,
2003b).
2.2. Glycodelin gene and mRNA.
The glycodelin gene is located on
chromosome 9q34 (Van Cong et al., 1991).
The gene consists of 5042 base pairs in seven
exons and six introns. The four putative
glucocorticoid/progesterone response
elements upstream in the promoter region
of the gene are located at positions –1799, -
1071, -745, and –302, and two additional,
downstream, at positions +1912 and +1965
(Vaisse et al., 1990). The gene encodes a 900-
bp long mRNA (Julkunen et al., 1988). Of
the many mRNA splicing variants (Garde
et al., 1991; Morrow et al., 1994; Koistinen
et al., 1997), some lack the sequences of the
glycosylation sites or the Threonine-Aspartic
acid-Tyrosine sequence typical of proteins of
the lipocalin family (Godovac-Zimmermann,
1988) or lack both. Both single nucleotide
polymorphisms (Van Cong et al., 1991) and
HinfI-restriction enzyme polymorphims are
known (Kämäräinen et al., 1991).
2.3. Temporal and spatial expression in normal
tissues
2.3.1. Female reproductive tract
In normal menstrual cycles, the expression
of glycodelin in the endometrial glands
usually begins 4 to 5 days after ovulation (LH
+4–5) (Seppälä et al., 1988b). Subsequently,
its concentration in tissue and uterine fluid
increases until the end of the cycle (Julkunen
et al., 1985; Julkunen et al., 1990; Li et al.,
1993b) (Table 1). Glycodelin is normally
absent from endometrium during the
proliferative phase, except for the first days
of the cycle, when glycodelin remains in the
basal glands (Julkunen et al., 1985; Julkunen
et al., 1986b; Waites et al., 1988b). During
pregnancy, glycodelin is synthesized by
decidualized endometrium and secreted into
the amniotic fluid (Julkunen et al., 1986b;
Julkunen et al., 1988; Julkunen et al., 1990).
The tissue concentration of glycodelin in
pregnancy decidua increases until the tenth
week. Thereafter, the synthesis decreases
towards the end of the pregnancy. In
maternal serum, glycodelin concentrations
are lower and follow the same pattern as in
endometrial tissue (Julkunen et al., 1985).
Glycodelin is present in the fallopian tubes
in conformity with the Müllerian origin of
the uterus and the fallopian tubes. No cycle-
dependent differences in glycodelin
concentrations occur in the isthmic and
ampullary parts of the Fallopian tubes, but
glycodelin concentrations in the fimbrial part
vary in a cyclical manner, the concentration
being higher in the secretory phase than in
the proliferative phase (Julkunen et al.,
1986d).
11
Review of the literature
In the normal ovary, glycodelin appears
in a variety of cells. In the follicular phase,
immunoreactivity occurs in the ovarian
cortex, theca interna, and granulosa. Luteal
phase cortical stroma is glycodelin-negative
or only weakly positive, whereas the theca
interna of the corpus luteum, corpus albicans,
Leydig cells of the ovarian hilus, and
luteinized granulosa cells are glycodelin-
positive (Kämäräinen et al., 1996).
Glycodelin mRNA appears in luteinized
granulosa cells, but not in cumulus cells (Tse
et al., 2002). Glycodelin is also present in
follicular fluid (Seppälä et al., 1985;
Chryssikopoulos et al., 1996) (Table 1).
Glycodelin synthesized by granulosa cells is
released into the follicular fluid, from whence
it is taken up by and partially modified by
the cumulus cells (Tse et al., 2002).
2.3.2. Male reproductive tract
Glycodelin protein and mRNA exist in
seminal vesicles and the ampulla of the vas
deferens, but not in the prostate, testis, or
epididymis. Glycodelin is present in seminal
fluid at high concentrations (Petrunin et al.,
1980; Bohn et al., 1982; Julkunen et al.,
1984; Koistinen et al., 1997).
2.3.3. Other cells and tissues
Glycodelin mRNA and/or protein also occur
in other glandular structures of the human
body, in mammary glands, sweat glands, and
bronchus epithelium (Kämäräinen et al.,
1997; Kämäräinen et al., 1999). Glycodelin
is present in megakaryocytes, platelets, and
megakaryotic cell lines (Morrow et al., 1994).
Erythroid precursor cells also synthesize
glycodelin (Kämäräinen et al., 1994).
Table 1. Glycodelin in female reproductive tissues, fluids, and peripheral serum
Origin
Endometrium
Mid-proliferative
Mid-secretory
Late secretory
Decidua
  9 week
40 week
Uterine flushings
Proliferative phase
Early secretory phase
Mid-secretory phase
Fallopian tube
Proliferative phase
Secretory phase
Amniotic fluid
12 week
16 week
40 week
Serum
Mid-proliferative phase
Mid-luteal phase
Late luteal phase
Menstrual
Pregnancy (12 weeks)
Pregnancy (40 weeks)
Follicular fluid
Glycodelin concentration
<0.1 mg/g protein
7.8 mg/g protein
23 mg/g protein
160mg/g protein
0.8 mg/g protein
Not detectable
Not detectable
12 mg/liter
4.3 µg/g protein
16 µg/g protein
13 mg/liter
125 mg/liter
1 mg/liter
<20 µg/liter
35 µg/liter
47µg/liter
74 µg/liter
1200 µg/liter
100 µg/liter
7.9-122 µg/liter
Author(s) (Reference)
Julkunen et al., 1986b
Julkunen et al., 1986b
Julkunen et al., 1986b
Julkunen et al., 1985
Julkunen et al., 1985
Li et al., 1993b
Li et al., 1993b
Li et al., 1993b
Julkunen et al., 1986d
Julkunen et al., 1986d
Julkunen et al., 1985
Julkunen et al., 1985
Julkunen et al., 1985
Julkunen et al., 1986b
Julkunen et al., 1986b
Julkunen et al., 1986b
Julkunen et al., 1986b
Julkunen et al., 1985
Julkunen et al., 1985
Seppälä et al., 1985
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2.4. Regulation of glycodelin synthesis in
endometrial and other cells
2.4.1. Progesterone, progestogens, and
antiprogestins
Evidence indicates that glycodelin expression
is related to the action of progesterone (Table
2). Glycodelin expression is confined to the
secretory and decidualized endometrium
(Julkunen et al., 1985; Julkunen et al.,
1986b), and its serum concentrations in-
crease in ovulatory cycles only, after the
progesterone levels have risen. In anovulatory
cycles, the glycodelin levels remain low
throughout the cycle (Julkunen et al.,
1986a). Micronized oral progesterone raises
the luteal phase serum glycodelin
concentrations in women with unexplained
infertility (Seppälä et al., 1987b). The
promoter region of the glycodelin gene
contains putative progesterone response
elements (Vaisse et al., 1990), and
Progesterone/
progestins
Estrogen
Evidence
+
+
+
+
-
+
+
-
-
Observation
Glycodelin expression is confined to the secretory and decidualized endometrium
Glycodelin serum levels increase only in ovulatory cycles - in anovulatory cycles glycodelin
levels remain low
Micronized oral progesterone increases the luteal phase glycodelin serum concentrations
in women with unexplained infertility
Postmenopausal women taking cyclical estrogen-progestogen replacement therapy have
elevated serum glycodelin  levels at the end of the progesterone treatment
No correlation between serum glycodelin and mid- or late luteal phase progesterone levels
in infertile women
Estrogen serum levels in proliferative phase are correlated with glycodelin levels in the luteal
phase in women undergoing ovarian hyperstimulation for in vitro fertilization
Positive correlation between serum estrogen levels and endometrial glycodelin
immunostaining between cycle days 12 and 24
Proliferative endometrium is glycodelin negative or shows only a very low glycodelin
content
Patients receiving estrogen only for hormone replacement therapy do not show elevated
serum glycodelin levels
Reference(s)
Julkunen et al., 1986b
Julkunen et al., 1985
Julkunen et al., 1986a
Seppälä et al., 1987b
Seppälä et al., 1987a
Check et al., 1991
Seppälä et al., 1989
Waites et al., 1989
Julkunen et al., 1986b
Byrjalsen et al., 1989
Table 2. Evidence for (+) or  against (-) stimulatory effects of progesterone/progestins and estrogen on glycodelin synthesis. Results from in vivo studies.
progestogens induce glycodelin in
endometrial cell cultures (Taylor et al., 1998;
Taylor et al., 2000). Ligand-activated
progesterone receptors stimulate glycodelin
gene expression through two active Sp1 sites
located in the glycodelin gene promoter
region (Gao et al., 2001).
In experimental settings in vitro, inter-
estingly, the antiprogestin mifepristone has
a stimulatory effect on glycodelin synthesis
(Taylor et al., 1998). Early pregnancy
interruption with mifepristone is associated
with a small increase in glycodelin serum
concentrations (Howell et al., 1989). Low
daily doses of mifepristone in women with
normal menstrual cycles, however, cause
retarded endometrial development and
decreased endometrial glycodelin expression
(Gemzell-Danielsson et al., 1996). Mife-
pristone may have inappropriate agonistlike
actions in some tissues and tumors.
Transcriptional coactivators, recruited to the
13
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transcription complex, may be responsible
for this phenomenon (Jackson et al., 1997).
2.4.2. Estrogen
Proliferative endometrium is glycodelin-
negative, and patients receiving estrogen
only for hormone replacement therapy show
no increase in circulating glycodelin
concentrations (Julkunen et al., 1986b;
Byrjalsen et al., 1989) (Table 2). In vitro,
estradiol has no effect on the transcriptional
activity of the glycodelin gene promoter
(Taylor et al., 1998). Serum estrogen levels
in the proliferative phase are, however,
correlated with glycodelin levels in the luteal
phase, suggesting that estrogen priming may
enhance glycodelin synthesis (Seppälä et al.,
1989; Li et al., 1992). Another study showed
a strong positive correlation in natural cycles
between serum estrogen levels and
endometrial glycodelin immunostaining
between cycle days 12 and 24 (Waites and
Bell, 1989). In conclusion, estrogen does not
directly induce glycodelin expression,
although its stimulatory effect may be
mediated by endometrial priming that
includes up-regulation of progesterone
receptors (Seppälä et al., 2002).
Relaxin 2.4.3.
The secretion of relaxin precedes by 1 to 2
days the secretion of glycodelin with a clear
positive correlation between them (Stewart
et al., 1997). The blood circulation of women
with no functional ovaries who become
pregnant through donated embryo transfer
lack relaxin (Emmi et al., 1991). In these
women, glycodelin levels are also low or
undetectable (Critchley et al., 1990;
Critchley et al., 1992; Johnson et al., 1993b).
Endometrial epithelial cells cultured with
porcine relaxin have shown a 2- to 6-fold
increase in glycodelin production rate, as
measured by the solution hybridization and
ribonuclease protection assays. That glyco-
delin mRNA concentration has increased
2 to 11-fold in cells incubated with relaxin
suggests that relaxin activates glycodelin
transcription (Tseng et al., 1999).
Although these studies indicate that
relaxin stimulates glycodelin synthesis, not
all studies support these observations.
Relaxin not only fails to induce de novo
production of glycodelin, it even represses
progesterone-stimulated activation of the
glycodelin promoter (Taylor et al., 2000).
Intravaginal administration of human
recombinant relaxin for induction of labor
does not affect glycodelin serum concen-
trations (Critchley et al., 1994). Women who
demonstrated normal ovarian cyclicity
showed sustained elevation of glycodelin
serum levels during a 28-day recombinant
human relaxin treatment, whereas those
without ovarian cyclicity or placebo-treated
women showed no elevation (Stewart et al.,
1997). Whereas the results of using
recombinant human relaxin have been
neither confirmed nor contested, the
mechanism of relaxin action on glycodelin
synthesis remains to be elucidated.
2.4.4. Other observations
During pregnancy, circulating levels of
glycodelin and hCG show similar patterns
(Seppälä et al., 2002). Investigations in
human beings show no evidence for any
stimulatory effect of hCG on endometrial
glycodelin secretion (Ren and Braunstein,
1990; Seppälä et al., 1991), whereas in
intact ovariectomized baboons, exogenous
hCG followed by progesterone and estrogen
treatment resulted in up-regulation of
glycodelin secretion between post-ovulation
days 18 and 25. Baboons treated only with
progesterone and estrogen showed no
increase in endometrial glycodelin synthesis
(Hausermann et al., 1998).
Erik Mandelin
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3. Glycodelin and reproduction
3.1. Inhibition of gamete interactions
Glycodelin-A and glycodelin-F isoforms
potently and dose-dependently inhibit the
binding of human sperm to the zona
pellucida (Oehninger et al., 1995; Chiu et
al., 2003a; Chiu et al., 2003b). The
contraceptive activity of these glycodelin
isoforms is mediated via unique
carbohydrate structures not present in
glycodelin-S (Morris et al., 1996; Chiu et
al., 2003a; Chiu et al., 2003b). The
contraceptive effects of glycodelin-A and -
F are likely to result from interaction
between glycodelin and the sperm rather
than between glycodelin and the oocyte
(Oehninger et al., 1995; Yao et al., 1998;
Chiu et al., 2003b), although in this
interaction zona pellucida proteins may also
be involved (Chiu et al., 2003a).
Glycodelin-F is a more potent inhibitor of
spermatozoa/zona pellucida binding than is
glycodelin-A, and is suggested to have two
binding sites on the sperm surface, whereas
glycodelin-A has only one (Chiu et al.,
2003a). This must be related to differing
glycodelin concentrations in uterine and
follicular fluids. Here, the glycodelin
concentration in uterine fluid exceeds by
orders of magnitude the concentration of
glycodelin immunoreactivity in preovula-
tory follicular fluid (Seppälä et al., 1985;
Li et al., 1993b). Importantly, the high
glycodelin concentrations such as in uterine
flushings and uterine tissue during the
midluteal phase of a normal menstrual cycle
can bring about a virtually complete
inhibition of sperm-egg binding (Julkunen
et al., 1986b; Li et al., 1993a; Li et al.,
1993b; Morris et al., 1996).
Glycodelin-F and glycodelin-A fail to
affect the spontaneous acrosome reaction of
human spermatozoa (Dutta et al., 2001;
Chiu et al., 2003a). Interestingly, after
progesterone induction, acrosome reaction
is inhibited by glycodelin-F, but not by
glycodelin-A (Chiu et al., 2003a). Non-
glycosylated recombinant glycodelin
improves capacitation of human
spermatozoa, whereas glycosylated
recombinant glycodelin inhibits both the
capacitation and the fertilization potential
of spermatozoa (Dutta et al., 2001).
3.2. Clinical perspectives
3.2.1. Fertilization window and glycodelin-
induced contraceptive activity of the uterus
The likelihood of fertilization is highest
during a 6-day period ending on the
estimated day of ovulation (Wilcox et al.,
1995). In the postovulatory phase, the
likelihood of fertilization decreases due to
changes in the cervical mucus that disturb
sperm motility. Glycodelin may also play a
role here. In a normal menstrual cycle, the
synthesis of glycodelin-A begins 5 days after
ovulation. Given its inhibitory effect on
sperm-egg binding, during the latter half
of the secretory phase, glycodelin may
contribute to the uterine contraceptive mic-
roenvironment. Here, absence of glycodelin-
A would be compatible with the fertile
window during the ovulatory midcycle to
enable spermatozoa to maintain their
fertilization capacity (Seppälä et al., 1997;
Seppälä et al., 1998b; Seppälä et al., 2002).
3.2.2. Glycodelin and oral contraceptives
The fact that glycodelin inhibits sperm-egg
binding has made glycodelin an interesting
model for contraceptive research. In this
context,  a  relevant  question  would  be
whether, during the fertile window, con-
traceptives currently used induce inappro-
priate glycodelin secretion. Glycodelin serum
levels and immunohistochemical localization
in endometrial tissues have been investigated
in women who use various combined oral
contraceptives (Wood et al., 1989). The
serum levels of the subjects remained at the
same low level throughout the cycle, similar
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to levels in natural cycles, irrespective of the
type of progestagen in the pill. This
phenomenon was noted in both serial and
individual samples from women taking
either monophasic or triphasic oral
contraceptives. However, immunohisto-
chemical analyses showed evidence of
induction of glycodelin synthesis.
Apparently, local endometrial glycodelin
synthesis was not sufficient to be reflected
in serum levels of the protein.
3.2.3. Emergency hormonal contraception
Two reports on the Yuzpe regimen both
involved two subsequent cycles of the same
woman: a control cycle and a treatment
cycle (hormone intake). In the first study,
ethinyl estradiol and norgestrel were given
on the ninth postovulatory day and resulted
in a decrease in serum and uterine fluid
glycodelin levels at day 11 postovulation
(Young et al., 1994). In the second study,
100µg ethinyl estradiol and 1mg
levonorgestrel were given in the treatment
cycle on the day of the LH surge, and the
treatment was repeated 12 hours later.
Endometrial biopsy was performed 8 to 10
days after the LH surge. No difference
appeared between control and treatment
cycles, as assessed by immunohistoche-
mistry, in glycodelin expression (Raymond
et al., 2000).
3.2.4. In vitro fertilization
The first report on pregnancies after IVF (in
vitro fertilization) and embryo transfer
demonstrated that glycodelin serum levels
increase markedly after implantation
(Julkunen et al., 1985). When the IVF
stimulation is made with clomiphene and
human menopausal gonadotropin, glyco-
delin serum levels first decline, reaching their
lowest level at the moment of oocyte
retrieval, and then rise again (Seppälä et al.,
1988a). No difference appeared in women
treated by IVF between fertile and infertile
treatment cycles in serum samples taken at
2- to 3-day intervals throughout the window
of implantation. Once pregnancy had been
established, however, glycodelin levels
increased markedly (Edwards, 1988). These
data suggest that glycodelin is not useful as
a predictor of implantation; rather, it reflects
endometrial response to implantation.
Another study compared late-luteal phase
serum glycodelin levels between conceivers
and nonconceivers, with higher levels among
conceivers. The results were, however,
inconclusive as to the greater likelihood of
the pregnancy’s continuing in women with
higher luteal phase glycodelin levels (Check
et al., 1992). Check and his co-workers
(1991) also investigated whether subnormal
glycodelin levels (serum levels and immuno-
histochemical staining) could be improved
by treating patients with therapies normally
used to correct endometrial defects. No
correlations appeared (Check et al., 1991).
These and other results indicate that because
serum glycodelin measurements fail to reflect
endometrial differentiation, they cannot
replace histological evaluation of the endo-
metrium (Batista et al., 1993a; Batista et al.,
1993b).
Serum glycodelin levels were investigated
during the implantation phase in cycles, both
successful and non-successful, during assisted
reproduction. All women undergoing
controlled ovarian hyperstimulation showed
a rise in glycodelin serum levels, a rise the
same regardless of the implantation or
induction therapy used (Wood et al., 1990).
These data suggest that glycodelin serum
levels fail to reflect local changes at the
implantation site. It is thus unlikely that
glycodelin serum measurements can provide
a tool for early detection of implantation or
of pregnancy.
First-trimester glycodelin serum con-
centrations have been compared between
women with:  1) natural conception,  2)
pituitary desensitization with buserelin and
ovarian stimulation with human menopausal
gonadotrophin followed by IVF and embryo
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transfer, 3) ovarian stimulation with clomi-
phene citrate and human menopausal gona-
dotropin followed by IVF and embryo
transfer. In normal pregnancies, glycodelin
levels increased 7- to 8-fold during weeks
4 and 10. This increase was, however, earlier
and less prominent in group 2 and was
absent from group 3 (Johnson et al., 1993a).
These findings suggest that following
ovarian stimulation, glycodelin synthesis is
altered in those pregnancies which do occur,
indicating changes in endometrial function.
3.3. Reproductive immunology in relation to
glycodelin
The human conceptus is not subject to the
laws of classical immunity. Despite their
being semi-allografts, the maternal immune
system does not reject embryos (Moffett-
King, 2002). Glycodelin reacts with many
cells of the immune system and may be one
of the factors contributing to the local
immunosuppressive microenvironment at
the fetomaternal interface. As immunological
factors appear to play a role in infertility and
in many pregnancy disorders (Gleicher et al.,
1989; Bowen et al., 2002), it is of interest to
note that women with a history of recurrent
miscarriages have lower glycodelin concen-
trations in uterine flushings and in serum
(Tulppala et al., 1995; Dalton et al., 1998).
Another finding of interest is that late
secretory phase glycodelin levels in uterine
flushings are significantly lower in patients
with unexplained infertility than in those of
normal controls (Mackenna et al., 1993).
Immunomodulatory functions of glycodelin
are illustrated in Table 3.
4. Glycodelin and cancer
4.1. Epithelial cancer of the ovary
Approximately 190 000 new cases of
ovarian cancer are diagnosed worldwide
Immunomodulatory functions of glycodelin
Inhibits thymidine uptake in mixed lymphocyte cultures and phytohemagglutinin-stimulated
lymphocytes
Decreases synthesis of IL-1 and IL-2 and release of soluble IL-2 receptors in mitogenically
stimulated lymphocytes and mononuclear cell cultures
Inhibits NK-cell cytotoxicity
Stimulates IL-6 production of secretory endometrial epithelial cells
Inhibits T cell proliferation
Binding of alpha2-macroglobulin to glycodelin potentiates the inhibitory effect of glycodelin
in T cell proliferation assays
Induces apoptosis of T cells
Inhibits chemotaxis of monocyte-like U937 cells
Elevates T cell receptor activation thresholds
Facilitates dephosphorylation of T cell receptor-induced phosphoproteins
Alters the dynamic sequestration of CD45 tyrosine phosphatase from T cell
receptor-triggered phosphoproteins
Potently inhibits E-selectin mediated cell adhesion
Author (s)  (reference)
Bolton et al., 1987
Pockley et al., 1988
Pockley and Bolton, 1989
and 1990
Okamoto et al., 1991
Laird et al., 1994
Rachmilewitz et al., 1999
Riely et al., 2000
Mukhopadhyay et al., 2001
Vigne et al., 2001
Rachmilewitz et al., 2001
Rachmilewitz et al., 2002
Rachmilewitz et al., 2003
Jeschke et al., 2003
Table 3.
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each year, with about 114 000 women
dying annually (Stewart and Kleihues,
2003), a higher mortality rate than for
any other gynecological malignancy. It is
the leading cause of death from cancer
in women in the western world (Beale
and Friedlander, 1995a). In 2000, Finland
had 436 new cases diagnosed (age-adjusted
incidence 9.5/100.000), ranking carcinoma
of the ovary the eighth most common female
cancer in the population. The predicted 5-
year relative survival rate between the years
1997 and 1999 was 42% (Finnish Cancer
Registry, 2003, www.cancerregistry.fi).
Centralization of surgical treatment may
further improve survival rates at the popu-
lation level (Kumpulainen et al., 2002). The
histological subtypes of ovarian carcinoma
are serous, mucinous, endometrioid,
transitional cell, clear cell, Brenner, and
undifferentiated. Serous is the most common
subtype, representing 40 to 70% of all
ovarian carcinomas (Beale and Friedlander,
1995b).
Radical debulking surgery is the corner-
stone of effective treatment of ovarian carci-
noma, essential for accurate staging, histo-
logical classification, grading, and risk
estimation, and for adjuvant chemotherapy
(Schilder et al., 1995). Whereas clinical stage
and histological grade are the gold standards
for clinical management, a great number of
diagnostic and prognostic markers have been
explored (Table 4). CA-125, the best-
evaluated tumor marker in ovarian
carcinoma, was found over 20 years ago (Bast
et al., 1981; Bast et al., 1983). It has
diagnostic (Bast et al., 1983; Jacobs et al.,
1990) and prognostic (Nagele et al., 1995;
Cooper et al., 2002) value, and  aids in the
evaluation of response to treatment and
detection of relapse. Due to its elevated
levels in many benign conditions, CA-125
is, however, unable to detect early stage
carcinomas and has low specificity (Mills et
al., 2001; Guppy and Rustin, 2002). A need
for new, more powerful diagnostic and
prognostic tools thus exists. This study
addressed the possible prognostic role of
glycodelin.
In ovarian carcinoma, glycodelin protein
and mRNA occur (Waites et al., 1990;
Kämäräinen et al., 1996; Horowitz et al.,
2001), but circulating levels of glycodelin
in ovarian carcinoma patients do not differ
from those in healthy individuals (Than et
al., 1988).
4.2. Endometrial adenocarcinoma
Although endometrial adenocarcinomas do
not synthesize glycodelin, treatment with
medroxyprogesterone acetate causes
glycodelin protein to appear in the regions
of normal histology among specimens from
endometrial cancer (Wood et al., 1988). In
keeping with the results concerning
adenocarcinoma tissue, glycodelin serum
levels in patients with endometrial
adenocarcinoma are not elevated (Than et al.,
1988). The Ishikawa endometrial cancer cell
line does not express glycodelin under
standard cell-culture conditions (Chatzaki et
al., 1994; Taylor et al., 2000).
The endometrial cancer cell line MFE-280
expresses both glycodelin protein and
mRNA (Hackenberg et al., 1998). RL95-2
endometrial cancer cells react with a
polyclonal antibody raised against a 16 amino
acid-long synthetic peptide (Gp) from amino
acids 69 to 83 of the glycodelin sequence
(Poddar et al., 1998; Horowitz et al., 2001;
Song et al., 2001). By use of this antibody,
increased Gp serum levels could be found in
endometrial, ovarian, and cervical cancer
patients (Horowitz et al., 2001). Glycodelin
mRNA and Gp appear in endometrial and
ovarian tumor tissues. The endothelium of
blood vessels of endometrial cancer shows
positive staining with the anti-Gp antibody,
whereas only very low immunoreactivity is
visible in normal endometrial tissues.
Immunosuppressive properties of glycodelin
are suggested to facilitate tumor growth in
gynecological malignancies (Song et al.,
2001).
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Diagnostic and prognostic biomarkers in ovarian carcinoma
Established biomarkers
CA 125
Carcinoembryonic antigen (CEA)
Free beta subunit of human chorionic gonadotropin
Tumor-associated trypsin inhibitor (TATI)
Potential biomarkers
Ovarian cystadenocarcinoma-associated antigen (OCAA)
Ovarian Cancer Antigens OvC1 and OvC6
Tissue polypeptide antigen (TPA)
HER-2/neu (p105)
Immunosuppressive acid protein (IAP)
Cancer-associated serum antigen (CASA)
AKT-2 gene
Cytokeratin fragment 21-1 (CYFRA 21-1)
Interleukin-6 (IL-6)
D-dimer
Lysophosphatidylcholine (lysoPC)
Plasminogen activator inhibitor 2 (PAI-2)
alpha-catenin
pKi67
Plasminogen activator inhibitor 1 (PAI-1)
Lysophosphatic acid (LPA)
Carboxyterminal telopeptide of type I collagen (ICTP)
Inhibin A
Matrix metalloproteinase-2 (MMP-2)
p53
Soluble members of the Mesothelin/ megakaryocyte potentiating
factor family
AIB1 gene amplification
Bax and Bcl-2
Estrogen and progesterone receptors
Soluble Fas
Colony stimulating factor-1 (CSF-1, M-CSF)
Human kallikrein 4
Human kallikrein 5
Prostasin
Cyclooxygenase-2 (COX-2)
Osteopontin
Proteomic patterns
Aminoterminal and carboxyterminal propeptides of type I collagens
Cyclin E
Human kallikrein 6
Human kallikrein 10
Vascular endothelial growth factor-D
Reference
Bast et al., 1983
Tuxen et al., 1995
Vartiainen et al., 2001
Stenman, 2002
Bhattacharya and Barlow, 1973
Imamura et al., 1978
Inoue et al., 1985
Slamon et al., 1989
Castelli et al., 1991
Ward et al., 1993
Bellacosa et al., 1995
Inaba et al., 1995
Scambia et al., 1995
Gadducci et al., 1996
Okita et al., 1997
Chambers et al., 1997
Anttila et al., 1998
Anttila et al., 1998
Chambers et al., 1998
Xu et al.,1998
Santala et al., 1999
Frias et al., 1999
Westerlund et al., 1999
Baekelandt et al., 1999
Scholler et al., 1999
Tanner et al., 2000
Baekelandt et al., 2000
Münstedt et al., 2000
Hefler et al., 2000
Xu et al., 1991;
Van Haaften-Day et al., 2001
Dong et al., 2001
Kim et al., 2001
Mok et al., 2001
Denkert et al., 2002
Kim et al., 2002
Petricoin et al., 2002
Simojoki et al., 2003
Farley et al., 2003
Diamandis et al., 2003
Luo et al., 2003
Yokoyama et al., 2003
Table 4.
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4.3. Glycodelin as a differentiation-related
morphogen
The endometrium undergoes monthly cycles
of proliferation and secretory activity
controlled by ovarian steroids. Estrogen
induces proliferation and hyperplasia of the
endometrial epithelium, and progesterone
transforms the endometrium from proli-
ferative into secretory, thereby creating a
suitable environment for embryo implanta-
tion. Glycodelin is a product of highly differ-
entiated endometrial secretory epithelium
(Julkunen et al., 1986b). Interestingly, the
ovarian surface epithelium in which approx-
imately 90% of human ovarian cancers are
believed to arise (Auersperg et al., 2001) is
glycodelin-negative (Kämäräinen et al.,
1996).
Regarding the wide glandular expression
of glycodelin, its role has been studied as a
differentiation marker and in glandular
morphogenesis. MCF-7 breast cancer cells do
not express glycodelin under normal cell
culture conditions, but transfection with
glycodelin cDNA causes dramatic changes
in cell growth behavior by suppression of
proliferation and formation of gland-like
structures. The transfected cells, due to
apoptosis, lose their ability to grow on
semisolid media and to express markers of
organized epithelia such as E-cadherin and
cytokeratins 8 and 18. Other alterations in
the transfected cancer cells include redistrib-
ution of β-catenin, upregulation of the α2
integrin subunit, and loss of the α6 integrin
subunit (Kämäräinen et al., 1997). In
summary, these results indicate that transfec-
tion of glycodelin cDNA can cause changes
resulting in less aggressive cell growth and
more advanced differentiation, suggesting
that glycodelin may play an active role as a
differentiation-related glandular morphogen.
Nor do Ishikawa endometrial cancer cells
synthesize glycodelin in normal cell culture
conditions (Chatzaki et al., 1994; Taylor et
al., 2000). When cocultured in the presence
of stromal cells and basement membrane
components, however, the cancer cells
resume concomitant differentiation and
glycodelin secretion (Arnold et al., 2002).
Glycodelin cannot be detected in normal
K562 erythroleukemia cells, whereas
treatment of the cells during 2 to 3 days with
tetradecanoylphorbol acetate brings about
differentiation and expression of both
glycodelin message and the protein
(Kämäräinen et al., 1994; Morrow et al.,
1994). Interestingly, during induced
differentiation, K562 cells become resistant
to NK-cell-mediated lysis (Gidlund et al.,
1981).
Erik Mandelin
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Aims of the Study
Given the contraceptive, immunosuppressive, and differentiative associations of glycodelin,
this study was designed to address the following questions:
1) Does the levonorgestrel-releasing intrauterine system induce glycodelin synthesis in
the endometrium during the period of the fertile window?
2) Can the levonorgestrel-releasing subdermal implant induce endometrial glycodelin
expression during the fertile window?
3) Does controlled ovarian hyperstimulation influence glycodelin expression during the
implantation window?
4) How is glycodelin expressed during the implantation window in the oocyte recipients´
mock cycles?
5) Is glycodelin expression in ovarian serous carcinoma associated with differentiation
and prognosis?
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Materials and Methods
1. Samples
Studies I, II, and V were approved by the
Ethics Committee of the Department of
Obstetrics and Gynecology, Helsinki
University Hospital, Study III by the
Institutional Review Board of the Eastern
Virginia Medical School, Norfolk, Virginia,
USA, and Study IV by the Institutional
Review Board of the New York Presbyterian
Hospital-Cornell University Medical
College, New York, New York, USA.
The tissue samples in Studies I to IV and
V originated from endometrium and from
ovary, respectively. All tissue samples were
formalin-fixed and paraffin-embedded.  In
Studies I to III, specimens were taken
prospectively, studies IV and V involved
archival samples (Table 5). Because endo-
metrial adenocarcinomas do not appear to
synthesize glycodelin (Wood et al., 1988),
we decided to investigate glycodelin expres-
sion in a clinical series of glycodelin-positive
ovarian serous carcinomas (Kämäräinen et al.,
1996).
2. Hormone treatments (III, IV)
The treatments were performed at the Jones
Institute for Reproductive Medicine
(Norfolk, VA, USA) and the Center for
Reproductive Medicine and Infertility at the
New York Presbyterian Hospital-Cornell
Medical College (New York, NY, USA). The
COH program of oocyte donors included
pituitary down-regulation with a GnRH
agonist (Lupron; TAP Pharmaceuticals,
Deerfield, IL, USA) starting in the mid-luteal
phase of the preceding natural cycle or 5 days
before the end of a cycle of oral contraceptives
(Damario et al., 1997), followed by admi-
nistration of gonadotropins FSH (Gonal-F;
Serono Laboratories, Norwell, MA, USA) or
Study
I
II
III
IV
V
Number of
patients
6
11
108
19
15
19
101
101
460
therapy/disease
LNG-IUD
copper-IUD
subdermal LNG-implant
postmenopausal controls
COH (oocyte donors)
normal controls
COH (oocyte donors)
mock cycles (oocyte recipients)
ovarian serous carcinoma
Patients treated at
Family Planning Unit, University of Jakarta, Jakarta, Indonesia
and  Femeda Gynecological Center, Helsinki, Finland
Family Planning Unit, University of Jakarta, Jakarta, Indonesia
Helsinki University Central Hospital, Helsinki, Finland
The Jones Institute for Reproductive Medicine, Norfolk,
Virginia, USA
The New York Presbyterian Hospital – Cornell University
Medical College, New York, USA
Helsinki University Central Hospital, Helsinki, Finland
Table 5. Subjects
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human menopausal gonadotropin (Pergonal;
Serono) or both. Ovarian response was
monitored by serial serum hormone meas-
urements and transvaginal ultrasound exami-
nation, with dosage of gonadotropins ad-
justed appropriately. Human chorionic
gonadotropin (Profasi; Serono) at a dose of
5 000 to 10 000 IU was given to each patient
to induce ovulation.
Oocyte recipients underwent a similar
program. Women with ovarian function
received leuprolide acetate for down-
regulation beginning in the mid-luteal phase
of the preceding menstrual cycle. Women
with no ovarian function received no GnRH-
agonist. Estrogen (Estraderm; Ciba Pharma-
ceutical Co., Summit, NJ, USA) and
progesterone (Progesterone-in-oil; Steris
Laboratories, Phoenix, AZ, USA) replace-
ment therapies were initiated on day 1 and
on day 15 of the mock cycle, respectively. In
the actual oocyte transfer cycle, progesterone
replacement therapy was initiated one day
before the donor’s oocyte retrieval, per-
mitting embryo transfer on cycle day 18.
3. Immunohistochemistry
3.1. Glycodelin (I–V)
The immunoperoxidase stainings were made
at the Helsinki University Central Hospital
according to Kämäräinen et al. (Kämäräinen
et al., 1996), with the only modification,
the inactivation of endogenous peroxidase,
being performed after incubation with the
secondary antibody. Briefly, the sections
(5µm) were deparaffinated and rehydrated
and then washed and subjected to
microwave heat treatment to enhance
immunoreactivity. Rabbit anti-glycodelin
IgG from two rabbits (rabbit #32 in Study
I and rabbit #1 in Studies II–V) served as
the primary antibody and preimmune
rabbit IgG as a negative control. Biotinyl-
ated porcine anti-rabbit immunoglobulins
(Dako A/S, Glostrup, Denmark) served as
secondary antibodies. Endogenous per-
oxidase activity was blocked by incubation
of sections in 0.6% perhydrol in methanol.
Immunostaining was then carried out with
the Vectastain ABC kit (Vector Labora-
tories, Burlingame, CA, USA), with 3-
amino-9-ethyl-carbazole as a substrate. All
sections were counterstained with hema-
toxylin. Secretory endometrium served in
the analyses as a positive control. Staining
specificity of rabbit #1 antibody was
monitored by absorbtion of the glycodelin
antibody with purified glycodelin (16 µg/
ml, overnight at +4º). No staining was
observable in control experiments. That both
antibodies #32 and #1 reacted identically
with purified glycodelin and amniotic fluid
in Western blot analysis indicated that the
antibodies were highly specific.
3.2. αvβ3 integrin (IV)
Immunoperoxidase stainings for the β3
integrin subunit were performed in the
USA at the University of North Carolina
at Chapel Hill with the SSA6 monoclonal
antibody (Lessey et al., 1994). Briefly, 8µm
thick formalin-fixed, paraffin-embedded
sections were dewaxed and rehydrated and
then blocked with 2% normal goat serum
to avoid eventual unspecific binding of the
second antibody. Overnight at +4ºC, these
sections were then incubated with the first
antibody (SSA6). Careful rinsing was
followed by incubation with a second
biotinylated goat anti-mouse antibody
(Vector). Immunoperoxidase staining was
performed with the Vectastain Elite ABC
kit (Vector), diaminobenzidine serving as
the substrate. Finally, all sections were
dehydrated and coverslips placed for micro-
spcopic examination.
3.3. Progesterone receptors A and B (V)
Stainings of PRA and PRB were performed
at Karolinska Institute in Stockholm, with
primary antibodies, generated in mice,
purchased from Novocastra (Newcastle
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upon Tyne, UK). PGR-312 antibody
recognizes PRA and PGR-AB-SAN27
antibody recognizes PRB (Mote et al.,
2001).
Paraffin sections (4 µm) were dewaxed
and rehydrated by standard procedures.
Endogenous peroxidase was blocked by
incubation in 1% hydrogen peroxide for 30
minutes, and antigen demasking performed
by microwaving (800 watts) sections in 0.01
M citrate buffer, pH 6.0, for 20 min. The
sections were incubated for 1 h at +4°C with
normal goat serum (1:10 in PBS). Primary
antibodies were diluted 1:100 in PBS
containing 3% bovine serum albumin and
incubated on the sections overnight at
+4°C. For negative controls, the primary
antibody was replaced with PBS alone. After
washing, the sections were incubated with
a biotinylated goat anti-mouse antibody
(1:200 dilution, Vector) at room tempera-
ture for 2 hours, followed by washing and
incubation with avidin-biotin-horseradish
peroxidase for one hour (Vectastain ABC-
kit, Vector). Diamino-benzidine (Dako)
served as substrate-chromogen for horsera-
dish peroxidase. Finally, the sections were
counterstained with Mayer’s hematoxylin
and dehydrated with graded ethanol
concentrations, followed by exposure to
xylene and mounting.
3.4. Double stainings for glycodelin and
progesterone receptor A or B (V)
At the Helsinki University Central Hos-
pital, stainings were carried out on 66
tumors with the PicTure™-Double
staining kit (Zymed Laboratories Inc., San
Francisco, CA, USA) according to the
manufacturer’s instructions. Briefly, the
sections were deparaffinized, rehydrated,
and subjected to microwave treatment to
enhance immunoreactivity. Endogenous
peroxidase activity was blocked with per-
hydrol in methanol. Nonspecific binding
of secondary antibodies was eliminated by
the kit’s own blocking solution. Primary
antibodies against glycodelin and PRA and
PRB were the same as above. The proge-
sterone receptor antibodies were diluted
1:300 in PBS. Anti-glycodelin IgG was
used at a concentration of 2.5 µg/ml (in
PBS). The first antibodies were incubated
concomitantly on tissue sections for 1.5
hours at room temperature. The two
secondary antibodies used according to kit
instructions were a horseradish peroxidase-
conjugated goat anti-mouse antibody for
the progesterone receptors and an alkaline
phosphatase-conjugated goat anti-rabbit
antibody for glycodelin. Substrate-chromo-
gens for horseradish peroxidase and alkaline
phosphatase were, respectively, diamino-
benzidine and Fast-Red. The sections were
counterstained with hematoxylin.
4. RNA in situ hybridization (I, II)
The RNA in situ hybridization was done
at the Helsinki University Central Hospital
according to a protocol adapted from Kois-
tinen et. al (1997). Briefly, the deparaffi-
nized tissue sections (5µm) were treated
with proteinase K and fixed with 4%
paraformaldehyde in PBS. In vitro trans-
cripts of sense and antisense probes were
prepared with a 413 base-pair cloned glyco-
delin cDNA serving as the template. After
the acetic anhydride treatment, hybridi-
zation was carried out with the use of a
digoxigenin-labeled RNA probe. After
washing, immunologic detection of the
digoxigenin-labeled RNA probe by means
of antidigoxigenin phophatase Fab frag-
ments (Boehringer-Mannheim, Mannheim,
Germany) was done according to the manu-
facturer’s instructions with Fast Red tablets
(Boehringer-Mannheim). Sections were
counterstained with hematoxylin.
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5. CA-125 (V)
Until 1995, CA-125 measurements were
carried out by routine immunoradiometric
assay (Centocor, Malvern, PA, USA), but
later, CA-125 levels were determined by
immunoenzymatic assay (Immuno1, Bayer,
Tarrytown, NY, USA), with a cut-off value
of 35 kU/L. At this level and higher the
two methods’ results were similar.
6. Statistical methods (I–V)
By the Kaplan-Meier method, survival
probabilities were calculated, and survival
curves between groups with different
glycodelin staining compared by log-rank
test. The Pearson Chi-Square test, Fisher’s
exact test, and the Mantel-Haenszel chi-
square test served for testing associations
between categorical variables, and Student’s
t-test for significance testing of normally
distributed data. Spearman rank correlation
and the Mann-Whitney U-test served for
significance testing of continuous non-
parametric data. The Wilcoxon rank sum and
Kruskal-Wallis tests served to compare
continous variables with categorical clinical
outcome. Binary logistic regression was used
for multivariate modeling of the correlation
between explanatory variables and the
glycodelin staining status, and analysis of
covariance to evaluate the association of
glycodelin with serum hormone levels. The
Cox proportional hazards model was used
in creating multivariate survival models. In
this case, the backward stepwise method
was used to select important variables. For
estimations of differences in 5- and 10-year
survival between the glycodelin-positive
and -negative groups, standard errors and
p-values were calculated for differences in
survival probabilities. A value of P < 0.05
was considered statistically significant.
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Results
1. Endometrial glycodelin expression
in the fertile midcycle in women
wearing the levonorgestrel-releasing
intrauterine device (I)
Endometrium from six LNG-IUD users was
analyzed by immunohistochemistry and in
situ hybridization during days 7 to 16, which
is the most fertile period of the menstrual
cycle. Endometrium from all the six LNG-
IUD-wearing women contained both
glycodelin protein and mRNA during
midcycle, regardless of the duration of IUD
use. Glycodelin was localized in the endo-
metrial glands, with only sporadic patches
in the stroma. Between different samples, the
staining intensity varied slightly. Glycodelin-
positive endometria was less frequent among
copper-IUD users (4 of 11 or 36%, P < 0.05).
In keeping with earlier results, the
endometrium of LNG-IUD-wearing women
showed epithelial atrophy and stromal
decidualization (Silverberg et al., 1986).
2. Endometrial glycodelin expression
of women using the subdermal
levonorgestrel-releasing contraceptive
implant (II)
Of the total of 108, endometrial glycodelin
staining was evident in 80%. Of 82
specimens from women with menstrual
periods, 69 (84%), and of 11 women with
oligomenorrhea, 7 (64%) stained positive for
glycodelin. Of the 12 women with levon-
orgestrel amenorrhea, 7 (58%) expressed
glycodelin in the endometrium. Glycodelin
expression was more common in women
with menstrual cycles than in those with
implant amenorrhea (P < 0.05). Of the 19
endometrial samples taken at fertile
midcycle, 89% stained glycodelin-positive.
Endometrial morphology showed prolifer-
ative (71%), inactive/weakly proliferative
(19%), menstrual or regenerating (6.5%), or
other patterns (2.8%). In these groups glyco-
delin was expressed in 79%, 71%, 100%,
and 100% of the cases. Among the four
groups of women, no significant differences
were apparent between morphologic patterns.
Glycodelin immunostaining score was
unrelated to age or to duration of implant
use. Women with irregular bleeding had used
the implant for a shorter time than had those
in other groups and were also older than those
women with menstrual periods or oligome-
norrhea.
None of the 19 samples from postmeno-
pausal women stained positive for glycodelin.
The difference in glycodelin staining between
the women with levonorgestrel amenorrhea
and hypoestrogenic amenorrhea was striking,
with 58% of the samples from the former
staining glycodelin-positive (P < 0.001).
By mRNA in situ hybridization, four of
the five specimens studied from the midcycle
of the women with levonorgestrel implants
showed positive staining for glycodelin. The
mRNA was localized to the glandular
epithelium only.
3. Endometrial glycodelin expression
in the luteal phase of stimulated
ovarian cycles (III)
Endometrial glycodelin expression was
investigated in 15 oocyte donors under-
going COH cycles and in 19 natural-cycle
Erik Mandelin
26
control patients; glycodelin was visualized
on day 16 of the menstrual cycle. Thereafter,
in both cycle types, glycodelin expression
increased, but with a relatively greater
proportion of cells staining in stimulated
cycles. A significant difference was
observable between natural and stimulated
cycles with respect to glycodelin staining
over standardized cycle days throughout the
window of embryo implantation (days 17–
24, P < 0.001). Confidence intervals no
longer overlapped at around days 20 to 21.
At that time, glycodelin scored on average
3.5 (range, 51–75% of cells staining) in
COH cycles, whereas the average glycodelin
score in natural cycles was about 2.5 (range,
26–50% of cells staining). Women under-
going COH showed advanced endometrial
histology (≥ 1day) in 42% of their glands
and in 70% of their stroma. A positive
correlation was demonstrable between
glycodelin and advanced glandular dating
(r = 0.63, P = 0.01).
Glycodelin was localized in endometrial
glands, not in the stroma or in the surface
epithelium. In natural cycles, endometrial
glycodelin showed a strong positive
correlation with serum estradiol (r = 0.5, P
< 0.001), but glycodelin and progesterone
did not correlate with each other. Nor did
any correlation appear in COH cycles
between glycodelin and either estradiol or
progesterone levels. No correlation was
evident between COH cycle biopsies and
progesterone/estradiol serum levels.
Luteinizing hormone serum levels correlated
with no other parameter analyzed.
4. Expression of glycodelin and αvβ3
integrin at midluteal phase utilizing
the donor oocyte model (IV)
The study’s 101 oocyte recipients had
undergone a mock hormonal treatment and
at least one oocyte recipient embryo transfer,
with hormonal protocols in mock and
treatment cycles being identical. An
endometrial biopsy was taken from all mock
hormonal-treated patients during cycle days
21 to 23. Mean age of the oocyte recipients
was 40.2 years. The mean number of oocytes
donated was 9.3 and those normally
fertilized, 6.0; and the mean number of
transferred embryos was 3.2. Overall
implantation rate per embryo transferred
was 30.9%, and clinical pregnancy and
delivery rates per transfer were 66.3 and
56.4%. Residual ovarian function existed
in 72 women, and these women were
treated with GnRH agonist in both mock
and actual treatment cycles. The other 29
women with documented ovarian failure
required no GnRH agonist down-
regulation. Clinical outcomes between
ovarian function and ovarian failure patients
did not significantly differ, except that the
latter were significantly younger and had a
higher mean number of normally fertilized
oocytes (P < 0.01 for both). Interestingly,
ovarian-failure patients seemed to exhibit
better implantation, pregnancy, and
delivery rates than did the ovarian function
subgroup, although none of these
differences reached statistical significance.
Histopathological analysis of the biopsies
from mock-treated cycles revealed 62
(61.3%) in-phase, 34  (33.7%) dyssynchro-
nous, 2 (2.0%) immature, and 3 (3.0%)
advanced endometria. The clinical outcomes
of in-phase and dyssynchronous endome-
trium were almost the same, including
implantation rate per embryo transferred
(32.5 vs. 29.9%), clinical pregnancy (66.1
vs. 67.6%), and delivery rates (56.5 vs.
55.9%). However, immunohistochemical
scores for glycodelin and αvβ3 differed
significantly (P < 0.001, for both) in the
two groups. Both glycodelin and αvβ3
integrin correlated strongly with endo-
metrial glandular dating (P < 0.001). This
was seen in the whole series and in the
subgroup of only cycle-day 22 and –23
patients. Immunohistochemical stainings of
both glycodelin and αvβ3 also correlated
with each other (P < 0.001).
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A lag in endometrial glandular
development, which usually is associated
with normal stromal development, was
relatively common on cycle day 21, but was
rare on day 23. On day 21, glycodelin and
αvβ3 integrin staining was often relatively
weak or absent. A considerable increase in
the immunohistochemical staining of
glycodelin and αvβ3 integrin was evident
over this time interval (P = 0.0001 for
both). No associations existed between
glycodelin/αvβ3 integrin immunohisto-
chemical scores and clinical outcome
parameters (implantation rate, clinical
pregnancy and delivery rates) by univariate
methodology. Because immunohistochem-
ical staining was fairly restricted and not
evenly distributed on day 21, a subset of
immunohistochemical staining results from
cycle days 22 and 23 were also analyzed by
the same methodology. These analyses,
however, failed to find any significant
associations between clinical outcome and
the two endometrial markers. Absence of
statistical power restricted the use of
statistical methods in the 23-day group
only. Neither the generalized estimating
equation models nor logistic regressions
predicting clinical outcomes using
endometrial markers and histological
characteristics showed associations for either
glycodelin or αvβ3 integrin.
5. Glycodelin in ovarian serous
carcinoma: associations with
differentiation and survival (V)
5.1. Glycodelin expression in tumor tissue
The flat surface epithelium of normal
postmenopausal ovary (n = 5) was glyco-
delin- negative in all cases but one, whereas
metaplastic cuboidal and columnar cells on
the ovarian surface and in the inclusion
invaginations and cysts stained weakly
positive for glycodelin. On the array slides,
specimens from 522 patients were initially
available. Due to loss of tissue during the
staining procedure, 460 patients remained
for the analysis. Glycodelin was localized in
the cytoplasm of malignant epithelial cells,
with vascular endothelium in tumor tissue
being glycodelin-negative. Of all tumors,
301 (65%) were glycodelin-positive and 159
(35%) glycodelin-negative. In the glyco-
delin-positive group, 214 (71%) showed
weak and 87 (29%) showed strong staining.
Evaluation of all immunohistochemical
stainings was based on the same criteria and
made by a single investigator. When less
than 50% of the cancer cells stained positive
for glycodelin, staining was considered weak
and when over half showed intense staining,
was considered strong.
5.2. Glycodelin expression and clinical
parameters
Glycodelin expression correlated with
tumor grade, so that percentages of glyco-
delin- positive tumors were, overall: grade
I, 79%; grade II, 63%; grade III, 51%
(Figure 1). Strong glycodelin staining was
less frequent among those with grade II
or III disease than with grade I tumors
(P < 0.0001). A similar trend toward a
decrease in glycodelin expression was
evident in tumors of advancing clinical
stage (P = 0.002, Figure 1). When both
grade and stage were included in the logistic
regression model to predict glycodelin
expression, grade remained the significant
variable (P < 0.0001).
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No difference was observable in initial
tumor size, age, or presence of ascites
between glycodelin-positive and -negative
subjects.  After primary debulking surgery,
residual tumors were more frequently (P <
0.001) small (<1cm) among glycodelin-
positive (148 of 250 or 59%) than among
negative patients (54 of 132 or 41%).
5.3. Glycodelin and survival in ovarian
cancer
Overall, patients with glycodelin-positive
tumors had a higher survival rate than did
the glycodelin-negative (Table 6, Figures 2
and 3), a difference notable for grade I
tumors (P = 0.0196) or stage III disease (P
= 0.0015) in which the 10-year survival
probability of the patients with glycodelin-
positive was more than twice that of the
patients with glycodelin-negative tumors (P
< 0.001, Table 6, Figure 3). Within certain
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Figure 1.  Relative frequencies of glycodelin-positive tumors in respect to A) tumor grade. Significant
differences observed between grade I tumors and grade II or III tumors  (P < 0.01**, P < 0.0001***).
B) tumor stage. Differences calculated by comparing stage II, III, and IV tumors each with stage
I tumors (ns=not significant, *P < 0.05, **P < 0.01).
well-defined clinical groups belonging to
the same clinical stage and differentiation
grade category, patients with glycodelin-
positive carcinoma showed, at certain time
points, better overall survival than did those
with glycodelin-negative carcinoma. This
was seen in the women with stage II/grade
III carcinoma at 5 years (P = 0.003), stage
III/grade II carcinoma at 10 years (P =
0.0001), stage III/grade III carcinoma at 10
years (P = 0.04), and stage IV/grade III
carcinoma at 5 years (P = 0.02).
In the whole series, survival in either
weakly or strongly staining groups was
better than that in the group with no
glycodelin staining (P < 0.001), whereas
between weakly and strongly staining
groups no difference appeared. Further
analyses were thus performed between the
glycodelin-positive and negative-groups,
without regard to staining intensity. When
the glycodelin expression status was entered
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Figure 2.
Cumulative survival of patients with glycodelin-positive vs. -negative tumors, including all subjects and
subjects stratified by histological grade. Gd = glycodelin.
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into the univariate Cox multiple hazards
model, the hazard ratio was 0.57 (CI 0.44-
0.74) for patients with glycodelin-positive
tumors. In the backwards stepwise selection
of multiple variables, glycodelin did not
emerge as an independent variable.
The possibility was considered that,
during long storage of tissue specimens,
intensity of immunohistochemical staining
may decrease. We controlled for this factor
by comparing staining intensities of
specimens taken during different periods.
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Figure 3. Cumulative survival of patients with glycodelin-positive vs. -negative tumors stratified by clinical
stage. Gd = glycodelin.
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Comparison of the first 230 patients treated
from 1964 to 1988 and the subsequent 230
patients treated from 1988 to 1999 showed
no significant difference in glycodelin
staining intensity. Staining was weak in 110
of 158 tumors (69.6%) and strong in 48 of
158 tumors (30.4%) in the earlier group,
and weak in 104 of 143 (72.7%) and strong
in 39 of 143 (27.3%) in the latter (Pearson
chi square test, P = 0.553). As with the
intensity, no significant difference appeared
in the relative number of glycodelin-
positive tumors between these two groups
(158 of 230 vs. 143 of 230; chi square test,
P = 0.141). In both groups, survival of those
patients with glycodelin-positive tumors
was higher than for those glycodelin-
negative (log rank test, P = 0.0001 and P =
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TABLE 6.  5- and 10-year overall survival rates of patients with glycodelin (Gd) positive and negative ovarian serous
carcinoma (ns=not significant,  a) p<0.05,   b) p<0.01,   c) p<0.001,  d) p<0.0001).
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0.0117, respectively). In backwards step-
wise selection of multiple variables, time
of diagnosis (binary variable: 1964-1988 or
1988–1999) remained an independent
prognostic factor (hazard ratio = 0.63; CI
low = 0.46, CI high = 0.85; P = 0.003),
showing that in the latter group the risk of
death was significantly smaller.
Regarding treatments that took place
before or after cisplatin, no difference existed
in intensity of glycodelin staining between
these groups. Among glycodelin-expressing
tumors treated before cisplatin, staining was
weak in 57 of 81 (70.4%) and strong in 24
of 81 (29.6%), and during cisplatin, was
weak in 157 of 220 (71.4%) and strong in
63 of 220 (28.6%, Pearson chi square test,
P = 0.866).  By log rank test, higher survival
remained significant for patients with
glycodelin-positive tumors, both before and
after cisplatin  (P = 0.0113 and P < 0.0001).
During the cisplatin period, survival signi-
ficantly improved (multivariate analysis,
hazard ratio = 0.54; CI low 0.38, CI high
0.77; P < 0.001).
Glycodelin-positive tumors were less
frequent after adoption of paclitaxel (53 of
97; 54.6%) than before it (248 of 363;
68.3%) (Pearson chi square test, P = 0.012),
with no significant difference in staining
intensity. Before paclitaxel, glycodelin-
positive staining was weak in 178 of 248
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(71.8%) and strong in 70 of 248 (28.2%)
tumors, and during paclitaxel staining was
weak in 36 of 53 (67.9%) and strong in 17
of 53 (32.1%) tumors (Pearson chi square
test, P = 0.575). Unlike in the other groups,
the paclitaxel group (n = 97), showed no
difference in survival between glycodelin-
positive and -negative tumors (P = 0.3498),
although the difference was highly
significant for the group before paclitaxel
(n = 363; P < 0.0001). In the multivariate
model, time of diagnosis (binary variable,
before or after adoption of paclitaxel) was
not an independent prognostic factor in the
paclitaxel group, probably because of the
small number of patients.
Despite improved diagnostic facilities,
carcinomas at a relatively more advanced
stage were referred for treatment at the
Helsinki University Hospital during the
period of more advanced chemotherapy.
This is illustrated by mean stage of disease
on admission, when the patients were
divided into various treatment categories.
Thus, in the first group of 230 patients
treated until 1988, the mean figure for stage
was 2.41 compared to 2.71 in the latter
group of 230 (Mann-Whitney test, P =
0.00035). The same trend appeared with
respect to adoption of cisplatin (2.35 vs.
2.63, P = 0.005) and paclitaxel treatments
(2.5 vs.2.78, P = 0.007)
5.4. Expression of progesterone receptor A and B
in tumor tissue in relation to glycodelin
expression
In the 460 ovarian serous tumors, PRA was
found in 33% and PRB in 14%. Where
present, both receptors were localized in
nuclei of the malignant cells. PRA was
present in 37% of the glycodelin-positive
and 26% of the -negative tumors (P < 0.02),
and PRB in 17% and 8% (P < 0.02). All
PRB-positive tumors also stained for PRA,
whereas only 44% of the PRA-positive
specimens were PRB-positive. In double
staining (n = 66), glycodelin and PRA/PRB
expression appeared in the same as well as
in different cells.
5.5. Serum CA-125-levels and endometrial
glycodelin expression
No correlation existed between serum CA-
125 levels and glycodelin immunostaining
status in tumors (P > 0.05, for all).
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Discussion
This study addresses three major areas in
which the differentiative association of
glycodelin appears to be important. The
first is the fertile window, in which absence
of contraceptive glycodelin is relevant for
fertilization, and induction of glycodelin
secretion would enhance the contraceptive
microenvironment within the uterus. The
second is the window of implantation, in
which the immunosuppressive effects of
glycodelin are likely to contribute to the
fetomaternal defense mechanisms. The
third area of the differentiative association
is related to cancer.
1. The fertilization window (I, II)
The fertilization window comprises the 5
days preceding ovulation and the day of
ovulation itself. During these 6 days,
intercourse is most likely to result in
pregnancy (Wilcox et al., 1995). The
mechanisms of action for IUDs can be
classified as occurring before or after
fertilization. Possible prefertilization me-
chanisms for IUDs include inhibition of
sperm migration and of viability (Moyer et
al., 1970; Sagiroglu, 1971; Croxatto et al.,
1973; Settlage et al., 1973; Tredway et al.,
1975; Koch, 1980), interference with ovum
development and transport (Ortiz and
Croxatto, 1987), and damage to or de-
struction of the ovum prior to fertilization
(Alvarez et al., 1988). The possible post-
fertilization mechanisms include destruction
or damage of the early embryo before or after
it has reached the uterine cavity and the
prevention of implantation (Ortiz and
Croxatto, 1987).
This study addressed another potential
prefertilization mechanism. Both glycodelin
protein and mRNA appeared in the
endometrium of LNG-IUD users in the
midcycle, when glycodelin is normally
absent (Julkunen et al., 1986b; Seppälä et
al., 1988b; Waites et al., 1988a). This
indicates that the glycodelin was induced
locally by levonorgestrel, by the IUD itself
as a foreign body, or by both. Of great
interest is the finding that all the LNG-IUD
wearers had glycodelin in their endo-
metrium throughout the otherwise fertile
phase of the cycle: the six-day period ending
in ovulation (Wilcox et al., 1995). Some of
the copper-IUD-wearing women also had
inappropriate glycodelin expression in the
endometrium. That this was less frequent
than among LNG-IUD-wearers suggests
that local progestogen can induce or enhance
endometrial glycodelin synthesis. The
effects of copper on induction of glycodelin
secretion remain to be elucidated.
Considering the potential contraceptive
effects of glycodelin (Oehninger et al., 1995;
Morris et al., 1996), these results are
significant because at the time when
spermatozoa migrate into the Fallopian
tubes, the uterine cavity is expected to be
free of contraceptive activity. Prior exposure
to endometrial glycodelin prevents
spermatozoa from binding to the zona
pellucida, with no effect from prior exposure
of the zonae to endometrial glycodelin
(Oehninger et al., 1995). Prior exposure to
endometrial glycodelin may thus provide a
mechanism by which in LNG-IUD-wearing
women, and also in some copper-IUD-
wearing women the fertilizing capacity of
the spermatozoa is reduced. This was not
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totally unexpected, because in post-
menopausal women cyclical oral estrogen/
progestagen replacement therapy raises
serum glycodelin in those whose uterus is
intact, but not in those with a hysterectomy
(Seppälä et al., 1987a).
Although we studied few women, our
tracking of glycodelin mRNA and protein
during the menstrual cycle’s periovulatory
phase anticipates larger clinical studies on
the consistency of glycodelin expression
outside its normal cyclical expression in
women wearing a LNG-IUD and other
types of IUD. Our study also raises the
possibility of a new contraceptive substance
that can inhibit fertilization.
Given the induction of glycodelin by
local application of levonorgestrel (I), we
hypothesized that levonorgestrel released
from subdermal contraceptive implants may
also cause inappropriate endometrial glyco-
delin expression. To evaluate this possible
effect, we studied endometrial biopsies from
our implant-wearing women. Endometrial
glycodelin expression appeared in 80% of
them. Of the specimens, 19 were taken
during the critical fertile 6-day period when
fertilization normally takes place (Wilcox
et al., 1995). Of these, 89% stained positive
for glycodelin. Because glycodelin is not
normally expressed in the endometrium
during this time of the cycle (Julkunen et
al., 1986b; Seppälä et al., 1988b; Waites et
al., 1988a), and considering the potential
contraceptive activity of glycodelin (Oeh-
ninger et al., 1995; Morris et al., 1996), the
appearance of endometrial glycodelin may
be yet another mechanism by which, in
women using levonorgestrel implants, the
fertilizing capacity of spermatozoa is
reduced.
Contrary to the case of women with LNG-
IUDs, not all of the specimens from LNG-
releasing subdermal implant-wearing
women contained glycodelin, perhaps be-
cause LNG from subdermal implants reaches
the endometrium systemically. Endometrial
LNG concentration is much lower after syste-
mic administration than is levonorgestrel
delivered locally from an LNG-IUD
(Croxatto et al., 1981; Nilsson et al., 1982).
In subdermal implant-wearing women,
serum levonorgestrel levels decrease with
increasing periods of use (Diaz et al., 1987),
so glycodelin expression was analyzed with
respect to length of implant use. That
glycodelin was not significantly affected by
length of use indicates that the LNG
concentration in long-term users must have
generally been adequate to induce
expression of endometrial glycodelin. Serum
levels of LNG and progesterone in LNG-
IUD- and subdermal implant-wearing
women are illustrated in Table 7.
Normal menstrual cycle
Postmenopausal women
COH-treatment cycles
LNG-IUD-wearing women
Subdermal LNG-implant-
wearing women
Steroid
Progesterone
Progesterone
Progesterone
Progesterone
Levonorgestrel
Progesterone
Levonorgestrel
Specifications
Follicular phase
Luteal phase
Follicular phase (prior to hCG
administration)
Ovulatory cycles (luteal phase)
Anovulatory women
During the first 3 months of treatment
After one year of treatment
Ovulating women (average peak value)
Anovulatory women
1-12 month of treatment
49-60 month of treatment
(nmol/l)
<6.0
6.0-64.0
<6.0
<2.9
>15.9
<4.8
0.8
0.4
29.6
<3.2
1.1
0.9
Reference(s)
Larsen et al., 2003
Wilson and Foster, 1985
Hofmann et al., 1993
Copperman et al., 1995
Nilsson et al., 1980
Nilsson et al., 1980
Nilsson et al., 1980
Nilsson et al., 1980
Croxatto et al., 1982
Croxatto et al., 1982
Croxatto et al., 1981
Croxatto et al., 1981
Table 7. Serum progesterone and levonorgestrel concentrations in different clinical contexts.
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Yet another interesting observation was
that the endometrium from women with
LNG-associated amenorrhea was more
likely to be glycodelin-positive; in hypo-
estrogenic amenorrhea the endometrium
was always glycodelin-negative, a difference
probably resulting from differing endocrine
microenvironments within the uterus.
What accounts for the difference observed
in glycodelin expression is certainly the
remaining ovarian activity in implant-
related amenorrhea (Xiao et al., 1995).
Levonorgestrel influenced endometrial
differentiation. In keeping with earlier
reports (Silverberg et al., 1986), irrespective
of duration of LNG-IUD use, major
morphological changes in endometrium
from LNG-IUD wearers were epithelial
atrophy and stromal decidualization. In
women wearing subdermal implants, the
difference between glycodelin-positive and
glycodelin-negative specimens was not
reflected in endometrial changes such as
these. Interestingly, unlike in normal cycles,
glycodelin staining was also evident in the
specimens with proliferative/inactive
endometrium from LNG implant users.
2. The implantation window (III, IV)
Of the two hormonally differing conditions
studied, the first (III), during the
implantation phase, was related to the
excessive hormonal microenvironment
following controlled ovarian hyperstimul-
ation of women with functional ovaries. This
is usually associated with multiple follicles
secreting estradiol and with multiple corpora
lutea following oocyte retrieval or ovulation.
In addition to estradiol and progesterone, the
corpus luteum also secretes relaxin. The
effects on glycodelin expression of such a
high- endocrine microenvironment was
another point of interest during the
implantation phase of the cycle.
The second study (IV) involving the
implantation phase addressed relative or
absolute ovarian failure as the cause of
infertility. This condition was treated by IVF
using donor oocytes, and it required estrogen/
progesterone replacement treatment in order
to achieve uterine receptivity. In the absence
of ovarian function, there existed none of the
woman’s own corpus luteum to secrete
progesterone and relaxin. Only progesterone
was replaced. Glycodelin expression during
such a low-endocrine microenvironment was
therefore of particular interest during the
implantation phase of the cycle, due to the
absence of ovarian relaxin secretion.
According to immunohistochemical
studies, endometrial glycodelin expression
begins in natural cycles 4 to 5 days after
ovulation (Seppälä et al., 1988b). This
corresponds to the glycodelin concentration
measured in endometrial tissue (Julkunen
et al., 1986b) and uterine fluid (Li et al.,
1993b). In this study, glycodelin expression
was evident in natural cycles as early as on
cycle day 16 (LH+3). Previous studies
estimated the phase of the menstrual cycle
by histological maturation, whereas the
present study employed accurate timing of
ovulation (LH surge). The start of glycodelin
secretion parallels the process of
implantation, in which the human embryo
penetrates the lining of the endometrial
epithelium sampled at LH +4/5 (Landgren
et al., 1996).
Some controversy exists as to the role of
relaxin in progesterone-regulated glycodelin
expression (Seppälä et al., 2002). This study
showed no correlation between glycodelin
and progesterone, which again indicates
temporal differences in secretion and a poss-
ible role for other factors. Our observation of
a strong positive correlation between serum
estradiol and glycodelin is an example of the
effects of estrogen priming, a fact in
agreement with earlier reports (Seppälä et al.,
1989; Li et al., 1992).
Endometrial glandular-stromal dyssyn-
chrony is relatively frequent in the mid-luteal
phase endometrium of women undergoing
mock cycles (Droesch et al., 1988). In this
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study, endometrial sampling in mock-
treated women was performed during the
menstrual cycle days 21 to 23, the period
generally considered to be the most repre-
sentative of the window of implantation
(Sarani et al., 1999; Acosta et al., 2000). As
in previous studies (Droesch et al., 1988),
oocyte recipients with glandular-stromal
dyssynchrony showed no disadvantage
compared with those with in-phase
endometria. For women with in-phase and
dyssynchronous endometria, clinical
pregnancy-, implantation-, and live-birth
rates were fairly similar. Curiously, succesful
pregnancies also occurred in women whose
endometrium showed retarded or advanced
glandular elements.
The clinical outcomes of women with at
least some residual ovarian function were
compared with outcomes of those with
ovarian failure, because only women in the
former group were treated with a GnRH
agonist. No differences appeared between
clinical outcomes of these two groups other
than a younger mean age and a greater mean
number of normally fertilized oocytes among
the ovarian failures, observations compatible
with earlier ones demonstrating that
treatment with a GnRH analog does not
affect implantation rates in women receiving
oocyte donation (Remohi et al., 1994).
Many putative markers of uterine re-
ceptivity have been explored (Lindhard et
al., 2002; Nikas and Aghajanova, 2002;
Stavreus-Evers et al., 2002; Aghajanova et
al., 2003). Two of them, glycodelin and
αvβ3 integrin, in the present study were
good markers of luteal phase glandular
maturity, with a strong correlation between
the immunostaining results of either marker
and endometrial glandular maturation.
Values for glycodelin and αvβ3 integrin
immunostaining also strongly correlated
with each other. These results are in line
with earlier ones suggesting that
diminished expression of αvβ3 integrin
and/or glycodelin is associated with retarded
endometrial differentiation (Klentzeris et
al., 1994; Krasnow et al., 1996; Meyer et
al., 1999).
None of the statistical models we used
was able to detect any association between
immunostaining intensities of glycodelin/
αvβ3 integrin and clinical outcome
variables (implantation rate, clinical
pregnancy, or live-birth rates). It would have
been of interest to focus on the chronological
subgroup with limited endometrial-
glandular dyssynchrony (cycle-day 23
group), but this was impossible due to lack
of statistical power.
One may speculate on why retarded en-
dometrial development – plus its associated
limited or absent expression of putative
markers of implantation – do not influence
outcome in mock treatment cycles. One
obvious explanation is the normal variation
between menstrual cycles, even in the same
individual. Another may be that in exo-
genous hormonal replacement cycles, the
window of implantation is simply shifted.
Retarded endometrial glandular histology
is often apparent in the mock cycles, and
when women receive oral micronized
estradiol instead of transdermal estradiol,
glandular histology is delayed even further
(Krasnow et al., 1996). Yet another possible
explanation may be that, due to a suboptimal
endometrial milieu, the embryo undergoes
diapause (Bergh and Navot, 1992; Tarin and
Cano, 1999), a physiological arrest well
described in other mammals (Spindler et al.,
1995; Song et al., 1998).
An alternative hypothesis is that endo-
metrial maturation, receptivity, and implan-
tation are all primarily determined by a
dialogue between the embryo and the
endometrium. Although this study was
unable to address the possible contribution
of embryo-derived signals, results from in
vivo and in vitro models suggest that hCG
can up-regulate both glycodelin and αvβ3
integrin (Simon et al., 1997; Hausermann
et al., 1998).
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3. Glycodelin and differentiation (V)
The postmenopausal ovary does not usually
express glycodelin, unlike the fertile phase
ovary, which has glycodelin present in
several cell types such as luteinized gra-
nulosa cells (Kämäräinen et al., 1996; Tse
et al., 2002). This difference may be related
to the postmenopausal ovary´s decreased
hormonal activity.
In ovarian carcinoma, glycodelin was
localized not in the vascular endothelium
of tumor tissues, but in the cytoplasm of
malignant cells. Studies employing anti-
glycodelin peptide (Gp) antibodies, which
react with vascular endothelial cells, show
a different pattern (Zhou et al., 2000; Song
et al., 2001). Because of the lack of glycodelin
mRNA in umbilical cord vein endothelial
cells, glycodelin peptide immunoreactivity
appears to result not from synthesis but
from uptake (Zhou et al., 2000). In ovarian
cumulus cells, similarly, glycodelin protein
exists but not its corresponding mRNA (Tse
et al., 2002). Regardless of differences in
immunolocalization, immunological
mimicry of the two types of antibodies is
obvious. The similarities of anti-Gp
antibodies and the conformational anti-
glycodelin antibodies need investigation to
reconcile their differentiative (glycodelin)
vs. angiogenic (Gp) associations (Song et al.,
2001; Arnold et al., 2002).
Of the 460 ovarian cancer patients in our
study, 65% of their tumors contained
glycodelin, its expression being more
common in the well-differentiated carci-
nomas that showed papillary or glandular
structures. One would have expected immu-
nohistochemical staining intensity to have
decreased during long storage of tissue
specimens as in this study, but this was not
the case, perhaps because glycodelin is stable
and well protected by its high carbohydrate
content. The proportion of glycodelin-
positive and -negative tumors remained
roughly similar over the long period of time
except that, after the adoption of paclitaxel
treatment, the frequency of glycodelin-
positive tumors was lower than for the
tumors treated before paclitaxel. This may
be related to the increased proportion of
advanced stage carcinomas referred for
treatment as the new treatment modalities
became available in the tertiary referral
centers. Paclitaxel is a cell-cycle-specific
drug that has dramatically improved the
prognosis of ovarian carcinoma. Its
efficiency may well be the reason why, in
this study, no difference appeared between
the survival of patients with glycodelin-
positive or -negative tumors in the
paclitaxel subgroup.
Changes in tumor grade are certainly
secondary to genetic and biochemical
changes that have taken place in the cells
undergoing neoplastic transformation.
Contact with the basement membrane
regulates epithelial cell growth and normal
organization (Capo-Chichi et al., 2002).
Both the basement membrane and the
stromal cells are required in this process so
that, prior to its emergence, the tumorigenic
phenotype must overcome the suppressive
effects of the surrounding microenviron-
ment (Roskelley and Bissell, 2002). Loss of
the basement membrane components
collagen IV and laminin may be an early
event in the pre-neoplastic transformation
of ovarian surface epithelium (Capo-Chichi
et al., 2002). The importance of the micro-
environment has been demonstrated by
experiments in which, when cocultured
with normal stromal cells and basement
membrane components, endometrial adeno-
carcinoma cells resume glycodelin secretion
and concomitant differentiation (Arnold et
al., 2002). Experiments on breast cancer
cells in which transfection of glycodelin
cDNA is followed by retarded growth, for-
mation of gland-like structures, and expres-
sion of epithelial cytokeratins (Kämäräinen
et al., 1997) provide further evidence for
the differentiative association of glycodelin,
suggesting that glycodelin is not only a
marker of epithelial differentiation but may
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play a fundamental role in glandular
morphogenesis. Reduced glycodelin
expression in poorly differentiated ovarian
cancer, unlike the case in well-differentiated
serous carcinomas, may be caused by de-
differentiation or loss of genetic material.
Genetic changes – both gains and losses –
are frequent in ovarian tumors (Pere et al.,
1998) and include a high frequency of
deletions at chromosome 9 (Devlin et al.,
1996) that harbors the glycodelin gene (Van
Cong et al., 1991).
Glycodelin and PRA/PRB frequently
occurred in the same malignant cells, but
not always. It is difficult to claim functional
association between the two, although this
cannot be ruled out because the glycodelin
gene consists of four putative gluco-
corticoid/progesterone response elements
(Vaisse et al., 1990). Both PRA and PRB
function as ligand-activated transcription
factors, but the two isoforms have differing
functional characteristics (Vegeto et al.,
1993; McDonnell and Goldman, 1994).
Ligand-activated PRA and PRB both
induce glycodelin expression in endometrial
adenocarcinoma cells in vitro (Gao et al.,
2001). Our positive correlation between
glycodelin and PRA and PRB in ovarian
cancer showed that both types of receptors
appeared in these glycodelin-expressing
cancers, even in the same cells. Because
many glycodelin-positive ovarian
carcinomas were progesterone-receptor-
negative, however, glycodelin expression
must also involve regulatory factors other
than progesterone.
Glycodelin expression was not related to
initial tumor size, but glycodelin-expressing
residual tumors were smaller. As this was a
retrospective observation, interpretation of
this observation remains speculative. A
simple interpretation would be better
operability of glycodelin-expressing tumors,
and this is also supported by survival data.
The finding that glycodelin does not
correlate with CA-125 levels was not totally
unexpected, as earlier studies indicate no
association between serum CA-125 levels
and histological grade of differentiation in
ovarian carcinoma (Tholander et al., 1990).
Concerning this association between
glycodelin and differentiation, not
surprisingly, those patients with glycodelin-
expressing tumors survived longer. This was
especially noticeable in patients with
histological grade I or clinical stage III
cancer. Trends were best seen in grade I and
stage III tumors probably because these
groups were sufficiently large to have
adequate power to detect differences unlike
other stages and grades with smaller
numbers of subjects which were therefore
much less likely to reveal any differences.
Whether glycodelin expression is primary
or secondary to the changes in tumor grade
emerging as an independent variable is as
yet undetermined.
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Summary and Conclusions
This study addressed the differentiation-
related propensity of glycodelin in three
clinically relevant contexts, the fertile
window, the window of implantation, and
ovarian carcinoma.
In studies on the fertile window, both
glycodelin protein and mRNA appeared in
the endometrium of users of the levo-
norgestrel-releasing IUD and subdermal
implant. This is the phase when glycodelin
is normally absent, indicating that glycodelin
expression was induced by levonorgestrel.
Appearance of endometrial glycodelin during
the fertile window may be one of the
mechanisms by which, in women using these
contraceptives, the fertilizing capacity of
spermatozoa is reduced. These results shed
light on the changes in endometrial micro-
environment during certain forms of contra-
ception, and potentially they offer new leads
for studies on other substances that may
reduce fertility by inducing inappropriate
endometrial glycodelin secretion.
In studies addressing the window of
implantation, oocyte donors who underwent
COH treatment had significantly higher
endometrial glycodelin expression
throughout the implantation window than
women with natural cycles. Endometrial
glandular-stromal dyssynchrony was rela-
tively common in the mock cycles of oocyte
recipients but did not affect clinical outcome.
Interestingly, in progesterone/estrogen-
stimulated mock cycles, endometrial
glycodelin expression was frequently present.
These results lend further support to the
importance of progesterone for glycodelin
synthesis.
In serous ovarian carcinoma, glycodelin
expression was more frequent in well
differentiated than in poorly differentiated
carcinomas and was also more frequent in
early- than in advanced-stage carcinomas.
Although in multivariate analysis glycodelin
was not an independent variable, patients
with glycodelin-expressing tumors showed
a higher 5-year overall survival  than did
those with glycodelin-negative tumors, a
difference notable in patients with grade I
tumors or stage III disease. In the latter
group, the 10-year survival probability of
patients with glycodelin-positive tumors was
more than twice that of women with
glycodelin-negative tumors. This was also
true within well-defined clinical categories,
e.g., in stage III/grade II and stage III/grade
III carcinomas, in which patients with
glycodelin-positive tumors had a signi-
ficantly better 10-year overall survival than
did those with glycodelin-negative tumors.
It can therefore be concluded that in ovarian
cancer, glycodelin is a differentiation-related
glycoprotein predicting better prognosis.
Earlier in vitro studies have revealed a
clear association between glycodelin and
cellular differentiation. The present study
shows how crucial this association can be
in a clinical context. It will be important
to investigate the cellular mechanisms un-
derlying glycodelin’s differentative actions.
Data concerning the effects of glycodelin
on expression of other genes and proteins
within a cell are still limited. Another
important issue is that signals from adjacent
cells and tissues can influence epithelial
glycodelin synthesis. For this purpose,
three-dimensional cell culture models
mimicking the in vivo endometrial
microenvironment may provide useful
information.
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